|
Index of reports
> Cases with Thrombocytopenia (98)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include thrombocytopenia. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of 98 Next >>
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-08-22
Patient: male
Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Mantle Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Mantle Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Mantle Cell Lymphoma
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-16
Patient:
Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Rituximab
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: on day 1
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphoma
Doxorubicin HCL
Dosage: on day 1
Rituximab
Dosage: maintenance
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Rituximab
Dosage: maintenance
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Rituximab
Dosage: maintenance
Indication: non-Hodgkin's Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Doxorubicin HCL
Dosage: on day 1
Doxorubicin HCL
Dosage: on day 1
Rituximab
Dosage: on day 1
Rituximab
Dosage: maintenance
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Doxorubicin HCL
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Indication: Lymphoma
Rituximab
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-01
Patient:
Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Indication: Waldenstrom's Macroglobulinaemia
Rituximab
Dosage: maintenance
Rituximab
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Waldenstrom's Macroglobulinaemia
Cyclophosphamide
Dosage: on day 1
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Waldenstrom's Macroglobulinaemia
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphocytic Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Rituximab
Dosage: maintenance
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Lymphoma
Rituximab
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Indication: Lymphocytic Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Indication: B-Cell Lymphoma
Rituximab
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Rituximab
Dosage: maintenance
Cyclophosphamide
Dosage: on day 1
Indication: Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: non-Hodgkin's Lymphoma
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Rituximab
Dosage: maintenance
Cyclophosphamide
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: B-Cell Lymphoma
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: non-Hodgkin's Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Waldenstrom's Macroglobulinaemia
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: Lymphocytic Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Lymphocytic Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Velcade
Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
Rituximab
Dosage: on day 1
Indication: Lymphoma
Rituximab
Dosage: maintenance
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: B-Cell Lymphoma
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Indication: Waldenstrom's Macroglobulinaemia
Velcade
Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
Rituximab
Dosage: on day 1
Cyclophosphamide
Dosage: on day 1
Vincristine
Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
Indication: Lymphoma
Prednisone
Dosage: on days 1-5
Administration route: Oral
Indication: non-Hodgkin's Lymphoma
Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron
Possible Vincristine side effects in
Reported by a physician from Italy on 2012-07-27
Patient:
Reactions: Anaemia, Skin Toxicity, Febrile Neutropenia, Mucosal Inflammation, Neurotoxicity, Respiratory Failure, Sepsis, Neutropenia, Cardiotoxicity, Septic Shock, Thrombocytopenia, Myocardial Infarction, Diffuse Large B-Cell Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Epirubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Prednisone and Prednisone
Indication: Diffuse Large B-Cell Lymphoma
Mabthera
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a physician from Italy on 2012-07-20
Patient:
Reactions: Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma Recurrent, Mucosal Inflammation, Neurotoxicity, Sepsis, Adverse Event, Cardiotoxicity, Neutropenia, Thrombocytopenia, Diffuse Large B-Cell Lymphoma, Lymphoma, Septic Shock
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 750 mg/m2 on day 1 for chop and 750 mg/m2 on day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2 on day 1 for chop and 50 mg/m2 on day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: 375 mg/m2 on day 1 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: 1.4 mg/m2 on day 1 for chop and 1.4 mg/m2 on day 2 for r-chop upto a maximum dose of 2 mg
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: 100 mg on days 1-5 for chop and r-chop
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in female
Reported by a physician from Germany on 2012-07-06
Patient: female
Reactions: Presyncope, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Rituxan
Dosage: 742.5 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Prednisolone
Dosage: 100 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Cyclophosphamide
Dosage: 1483 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Doxorubicin HCL
Dosage: 100 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Neulasta
Dosage: 6 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Vincristine
Dosage: 3.94 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Other drugs received by patient: Ramipril; Nebivolol; Tiotropium Bromide; Levothyroxine Sodium; Trimethoprim + Sulfamethoxazole; Acyclovir; Simvastatin; Torsemide; Acetylsalicylic Acid SRT; Enoxaparin Sodium; Pantoprazole
Possible Vincristine side effects in
Reported by a physician from United States on 2012-07-06
Patient:
Reactions: Stomatitis, Hepatic Failure, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Haematotoxicity, Cardiac Disorder, Neutropenia, Thrombocytopenia, Renal Failure Acute
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Neulasta
Dosage: on day 2 of a 14 day cycle
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: day 1-5
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: 2 mg max
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxil
Dosage: cohort 1: 20 mg/m2 cohort ii: 25 mg/m2 cohort iii: 30 mg/m2
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a physician from South Africa on 2012-07-05
Patient:
Reactions: Pneumonia, Hepatotoxicity, Anaemia, Tuberculosis, Hyponatraemia, Kaposi's Sarcoma, Thrombocytopenia, Generalised Oedema
Drug(s) suspected as cause:
Lamivudine Stavudine Nevirapine
Indication: Kaposi's Sarcoma AIDS Related
Vincristine
Dosage: capped at 2 mg
Indication: Kaposi's Sarcoma AIDS Related
Doxorubicin HCL
Indication: Kaposi's Sarcoma AIDS Related
Etoposide
Dosage: 50-100 mg for 1-21 days of a 28 day cycle.
Administration route: Oral
Indication: Kaposi's Sarcoma AIDS Related
Bleomycin Sulfate
Dosage: 10 u/m2
Indication: Kaposi's Sarcoma AIDS Related
Possible Vincristine side effects in 67 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02
Patient: 67 year old male
Reactions: Weight Decreased, Anaemia, Acute Phosphate Nephropathy, Mental Status Changes, Hypercalcaemia, Hyperuricaemia, Haemodialysis, Tumour Lysis Syndrome, Renal Impairment, Oliguria, Leukocytosis, Thrombocytopenia, Decreased Appetite, Renal Failure Acute, Hepatosplenomegaly
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Indication: Chemotherapy
Vincristine
Indication: Chemotherapy
Dexamethasone Sodium Phosphate
Indication: Chemotherapy
Cyclophosphamide
Indication: Chemotherapy
Possible Vincristine side effects in female
Reported by a physician from Germany on 2012-06-28
Patient: female
Reactions: White Blood Cell Count Decreased, C-Reactive Protein Increased, Sepsis, Hypotension, Presyncope, Neutropenia, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Mabthera
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Neulasta
Dosage: daily dose 6 mg, 2 x(29 apr 2012+17 may 2012
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Prednisolone
Dosage: frequency 1 times in 2 week for 5 days
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Other drugs received by patient: Enoxaparin Natrium; Aspirin; Ramipril; Tiotropium Bromide; Nebivolol; Torsemide; Pantoprazole; Levothyroxine Sodium; Acyclovir; Simvastatin; Trimethoprim + Sulfamethoxazole
Possible Vincristine side effects in
Reported by a physician from France on 2012-06-27
Patient:
Reactions: Febrile Neutropenia, Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma, Thrombocytopenia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Rituximab
Dosage: on day 1, every 21 days for 6 cycles
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1, every 21 days for 6 cycles
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Dosage: on day 1, every 21 days for 6 cycles
Indication: Diffuse Large B-Cell Lymphoma
Granulocyte Colony Stimulating Factor
Indication: Diffuse Large B-Cell Lymphoma
Prednisolone
Dosage: on days 1-5, every 21 days for 6 cycles
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 1, every 21 days for 6 cycles
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a individual with unspecified qualification from Korea, Republic of on 2012-06-26
Patient:
Reactions: Abdominal Pain, Hyperbilirubinaemia, Anaemia, Alanine Aminotransferase Increased, Febrile Neutropenia, Rash, Pyrexia, Peripheral Sensory Neuropathy, Diarrhoea, Alopecia, Aspartate Aminotransferase Increased, Neutropenia, Asthenia, Thrombocytopenia
Drug(s) suspected as cause:
Vincristine
Dosage: given on day 1 of every cycle; dose: 1.4 mg/m2 ( maximum 2.0 mg)
Indication: B-Cell Lymphoma
Prednisolone
Dosage: given on days 1 to 5 of every cycle (repeated every 3 weeks)
Administration route: Oral
Indication: B-Cell Lymphoma
Mabthera
Dosage: on day 1 of every cycle
Indication: B-Cell Lymphoma
Cyclophosphamide
Dosage: given on day 1 of each cycle
Indication: B-Cell Lymphoma
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-22
Patient:
Reactions: Performance Status Decreased, Pain, Abdominal Pain Upper, Fatigue, Neutropenic Infection, Thrombocytopenia, Hallucination, Dyspnoea, Vomiting, Nausea, Hyperglycaemia, Haemoglobin Abnormal, Pancytopenia, Febrile Neutropenia, Toxicity To Various Agents, Haemoglobin, Neutropenia, Diffuse Large B-Cell Lymphoma, Cardiovascular Disorder, Leukopenia, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Vincristine
Dosage: 6-8 cycles
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Granulocyte Macrophage Colony Stim Factor
Dosage: days 3-10
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Dosage: 6-8 cycles
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: 6-8 cycles
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: 6-8 cycles
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Anti-Emetics; Dapsone; Trimethoprim + Sulfamethoxazole
Possible Vincristine side effects in male
Reported by a physician from Italy on 2012-06-14
Patient: male
Reactions: Epstein-Barr Virus Infection, Anaemia, Cytomegalovirus Infection, Neutropenia, Thrombocytopenia, Disease Progression, Infection
Drug(s) suspected as cause:
Carmustine
Indication: Burkitt's Lymphoma
Carboplatin
Indication: Burkitt's Lymphoma
Rituximab
Indication: Burkitt's Lymphoma
Etoposide
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Burkitt's Lymphoma
Vincristine
Indication: Burkitt's Lymphoma
Melphalan Hydrochloride
Indication: Burkitt's Lymphoma
Radiotherapy
Indication: Burkitt's Lymphoma
Cyclophosphamide
Indication: Burkitt's Lymphoma
Cisplatin
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Burkitt's Lymphoma
Ifosfamide
Indication: Burkitt's Lymphoma
Granulocyte Colony Stimulating Factor
Indication: Burkitt's Lymphoma
Methylprednisolone
Indication: Burkitt's Lymphoma
Unknown Medication
Dosage: antimicrobial prophylaxis
Indication: Burkitt's Lymphoma
Other drugs received by patient: Unknown Medication
Possible Vincristine side effects in
Reported by a individual with unspecified qualification from United States on 2012-06-11
Patient:
Reactions: Nausea, Bacteraemia, Anaemia, Hypoalbuminaemia, Abscess, Neutropenia, Thrombocytopenia, Decreased Appetite
Drug(s) suspected as cause:
Azacitidine
Cyclophosphamide
Dosage: for 6 to 9 days
Indication: Lymphoma
Vincristine
Dosage: for 8 days
Indication: Lymphoma
Mabthera
Dosage: for 8 days
Indication: Lymphoma
Azacitidine
Indication: Lymphoma
Possible Vincristine side effects in female
Reported by a physician from Germany on 2012-06-07
Patient: female
Reactions: Syncope, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1483 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Vincristine
Dosage: 3.94 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Neulasta
Dosage: unk
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Rituximab
Dosage: 742.5 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Prednisolone
Dosage: 100 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Doxorubicin HCL
Dosage: 100 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Other drugs received by patient: Acetylsalicylic Acid SRT; Simvastatin; Acyclovir; Nebivolol; Pantoprazole; Torsemide; Levothyroxine Sodium; Tiotropium Bromide; Trimethoprim + Sulfamethoxazole; Enoxaparin Sodium; Ramipril
Possible Vincristine side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-05
Patient: male, weighing 102.6 kg (225.7 pounds)
Reactions: Cardio-Respiratory Arrest, Respiratory Failure, Anaemia, Troponin I Increased, Thrombocytopenia, Infection
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Methotrexate
Dosage: 1600 mg, cyclic
End date: 2011-07-28
Adriamycin PFS
Dosage: 101 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-05
End date: 2011-07-05
Rituximab
Dosage: 750 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-01
End date: 2011-07-26
Methotrexate
Dosage: 400 mg, cyclic
Indication: Mantle Cell Lymphoma
End date: 2011-07-27
Cytarabine
Dosage: 6 g, cyclic
Indication: Mantle Cell Lymphoma
End date: 2011-07-30
Dexamethasone
Dosage: 40 mg, cyclic
Indication: Mantle Cell Lymphoma
Dexamethasone
Dosage: 20 unk, unk
Administration route: Oral
End date: 2011-07-15
Vincristine
Dosage: 2 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-05
End date: 2011-07-12
Velcade
Dosage: 2.6 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-01
End date: 2011-07-26
Cyclophosphamide
Dosage: 603 mg, cyclic
Indication: Mantle Cell Lymphoma
Start date: 2011-07-02
End date: 2011-07-04
Other drugs received by patient: Filgrastim; Ferrous Sulfate TAB; Heparin; Senokot; Triamcinolone Acetonide; Compazine; Ciprofloxacin; Fluconazole; Omeprazole; Mesna; Prevident; Valtrex; Vitamin C / 00008001 /; Methylprednisolone; Periogard; Ultram; Vitamin D
Possible Vincristine side effects in female
Reported by a physician from Germany on 2012-06-04
Patient: female
Reactions: Syncope, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1483 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Doxorubicin HCL
Dosage: 100 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Prednisolone
Dosage: 100 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Vincristine
Dosage: 3.94 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Neulasta
Dosage: unk
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Rituximab
Dosage: 742.5 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Other drugs received by patient: Nebivolol; Torsemide; Tiotropium Bromide; Enoxaparin Sodium; Trimethoprim + Sulfamethoxazole; Pantoprazole; Simvastatin; Acetylsalicylic Acid SRT; Ramipril; Acyclovir; Levothyroxine Sodium
Possible Vincristine side effects in female
Reported by a physician from Germany on 2012-06-01
Patient: female
Reactions: Syncope, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mabthera
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Prednisolone
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Neulasta
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Other drugs received by patient: Nebivolol; Tiotropium Bromide; Acetylsalicylic Acid SRT; Ramipril; Acyclovir; Pantoprazole; Levothyroxine Sodium; Trimethoprim + Sulfamethoxazole; Enoxaparin Natrium; Simvastatin; Torsemide
Possible Vincristine side effects in
Reported by a physician from Germany on 2012-06-01
Patient:
Reactions: Respiratory Disorder, Pain, Myelodysplastic Syndrome, Pyrexia, Neoplasm, Death, Completed Suicide, Thrombocytopenia, Vomiting, Nausea, Anaemia, Acute Myeloid Leukaemia, Toxicity To Various Agents, Haematotoxicity, Hodgkin's Disease, Mucosal Inflammation, Accident, Alopecia, Gastrointestinal Disorder, Nervous System Disorder, non-Hodgkin's Lymphoma, Cardiovascular Disorder, Leukopenia, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Hodgkin's Disease
Etoposide
Indication: Hodgkin's Disease
Vincristine
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Indication: Hodgkin's Disease
Prednisone TAB
Indication: Hodgkin's Disease
Doxorubicin HCL
Indication: Hodgkin's Disease
Bleomycin Sulfate
Indication: Hodgkin's Disease
Other drugs received by patient: Radiotherapy
Possible Vincristine side effects in
Reported by a individual with unspecified qualification from France on 2012-06-01
Patient:
Reactions: Ejection Fraction Decreased, Febrile Neutropenia, Troponin T Increased, Neutropenia, Thrombocytopenia, Cardiac Failure Congestive, Infection
Drug(s) suspected as cause:
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Mabthera
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Indication: Diffuse Large B-Cell Lymphoma
Pixantrone
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in 38 year old female
Reported by a physician from United States on 2012-06-01
Patient: 38 year old female
Reactions: Neutropenia, Thrombocytopenia
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-13
Mesna
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-13
Doxorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Dasatinib
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-04-13
Possible Vincristine side effects in female
Reported by a physician from Germany on 2012-05-30
Patient: female
Reactions: Syncope, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Mabthera
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Doxorubicin HCL
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Neulasta
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Cyclophosphamide
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Prednisolone
Indication: B-Cell Lymphoma
Start date: 2012-04-26
End date: 2012-04-30
Vincristine
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Other drugs received by patient: Nebivolol; Trimethoprim + Sulfamethoxazole; Enoxaparin Natrium; Levothyroxine Sodium; Acyclovir; Simvastatin; Torsemide; Tiotropium Bromide; Ramipril; Pantoprazole; Aspirin
Possible Vincristine side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-05-28
Patient: female
Reactions: Foetal Growth Restriction, Premature Baby, Anaemia, Thrombocytopenia
Adverse event resulted in: life threatening event
Drug(s) suspected as cause:
Doxorubicin HCL
Cyclophosphamide
Vincristine
Ifosfamide
Dosage: 1df= 9g/m3 over 5 days.
Indication: Ewing's Sarcoma
Possible Vincristine side effects in female
Reported by a physician from Germany on 2012-05-28
Patient: female
Reactions: Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Prednisolone
Dosage: 100 mg, unk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Vincristine
Dosage: 3.94 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Rituximab
Dosage: 742.5 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-25
Cyclophosphamide
Dosage: 1483 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Neulasta
Dosage: unk
Indication: B-Cell Lymphoma
Start date: 2012-04-29
Doxorubicin HCL
Dosage: 100 mg, q2wk
Indication: B-Cell Lymphoma
Start date: 2012-04-26
Other drugs received by patient: Enoxaparin Sodium; Tiotropium Bromide; Trimethoprim + Sulfamethoxazole; Levothyroxine Sodium; Ramipril; Acyclovir; Nebivolol; Simvastatin; Torsemide; Pantoprazole; Acetylsalicylic Acid SRT
Possible Vincristine side effects in 18 year old female
Reported by a health professional (non-physician/pharmacist) from France on 2012-05-28
Patient: 18 year old female
Reactions: Oligohydramnios, Normal Newborn, Anaemia, Febrile Neutropenia, Neutropenia, Pregnancy, Thrombocytopenia
Drug(s) suspected as cause:
Neupogen
Indication: Rhabdomyosarcoma
Dactinomycin
Dosage: q21d
Indication: Rhabdomyosarcoma
Vincristine
Indication: Rhabdomyosarcoma
Cyclophosphamide
Dosage: 1 df: 2.2g/m2
Indication: Rhabdomyosarcoma
Mesna
Indication: Rhabdomyosarcoma
Possible Vincristine side effects in female
Reported by a individual with unspecified qualification from United States on 2012-05-25
Patient: female, weighing 14.9 kg (32.8 pounds)
Reactions: Anaemia, Hyponatraemia, Rash, Pyrexia, Ascites, Abdominal Pain Upper, Abdominal Compartment Syndrome, Respiratory Failure, Pneumonia Herpes Viral, Bone Marrow Failure, Neutropenia, Thrombocytopenia, Cardiac Arrest, Septic Shock, Infection in AN Immunocompromised Host
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Vincristine
Dosage: .99 mg
Methotrexate
Dosage: 24.5 mg
Dexamethasone
Dosage: 17.5 ml
Mercaptopurine
Dosage: 460 mg
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-05-08
Patient:
Reactions: Neuropathy Peripheral, Pneumonia, Diabetes Mellitus, Sepsis, Anaemia, Neutropenia, Thrombocytopenia, Disease Progression, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Dexamethasone
Indication: Multiple Myeloma
Thalomid
Dosage: 100 milligram
Administration route: Oral
Indication: Multiple Myeloma
Bortezomib
Indication: Multiple Myeloma
Bortezomib
Vincristine
Indication: Multiple Myeloma
Adriamycin PFS
Indication: Multiple Myeloma
Other drugs received by patient: Aspirin; Neupogen; Melphalan Hydrochloride
Possible Vincristine side effects in 49 year old female
Reported by a health professional (non-physician/pharmacist) from Taiwan, Province of China on 2012-05-03
Patient: 49 year old female
Reactions: Erythema Infectiosum, Hepatitis Acute, Thrombocytopenia, Leukopenia
Drug(s) suspected as cause:
Epirubicin
Dosage: 6-cycles
Indication: Intestinal T-Cell Lymphoma
Cyclophosphamide
Dosage: 6 cycles
Indication: Intestinal T-Cell Lymphoma
Vincristine
Dosage: 6-cycles
Indication: Intestinal T-Cell Lymphoma
Rituximab
Indication: Intestinal T-Cell Lymphoma
Dexamethasone
Dosage: 6-cycles
Indication: Intestinal T-Cell Lymphoma
Other drugs received by patient: Lamivudine
Possible Vincristine side effects in
Reported by a physician from France on 2012-04-26
Patient:
Reactions: Electrocardiogram QT Prolonged, Dyspepsia, Adverse Event, Neutropenia, Thrombocytopenia, Hepatic Enzyme Increased
Drug(s) suspected as cause:
Doxorubicin HCL
Indication: T-Cell Lymphoma
Prednisone
Indication: T-Cell Lymphoma
Romidepsin
Dosage: escalating doses
Indication: T-Cell Lymphoma
Vincristine
Indication: T-Cell Lymphoma
Cyclophosphamide
Indication: T-Cell Lymphoma
Romidepsin
Page 1 Next >>
|
